StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
NASDAQ:PULM opened at $2.09 on Tuesday. Pulmatrix has a 1 year low of $1.55 and a 1 year high of $2.75. The stock has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $1.99. The stock has a market capitalization of $7.63 million, a price-to-earnings ratio of -0.88 and a beta of 0.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The company had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- Investing in Construction Stocks
- When Is the Best Time to Invest in Mutual Funds?
- Best Aerospace Stocks Investing
- Is NVIDIA Stock in a Correction or Consolidation?
- How to Buy Cheap Stocks Step by Step
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.